TSTapani Salonen

Tapani Salonen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tapani Salonen has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Structured Outpatient Peritoneal Dialysis Catheter Insertion is Safe and Cost-Saving

    by Tapani E. Salonen, Heikki Saha

    Background: Data about outcomes and costs for peritoneal catheter insertion on an outpatient basis are scarce. Methods: Using patient files, all peritoneal dialysis (PD) catheter insertions performed between 2004 and 2009 in a single-center tertiary care institution for adult patients were located. Patient demographics, complications, hospitalizations, survival, and treatment modality changes were recorded. Procedure-related expenses were valued as actual production costs. Results: During the study period, 106 PD catheters were inserted. In 46 cases, the patients were admitted electively for catheter insertion; 19 catheters were placed during admission for other medical reasons; and 41 catheters were placed on an outpatient basis. Among the study patients (54.7 ± 16.0 years of age), 45% were diabetic. Early (<30 days) catheter-related complications occurred in 22% of patients. The incidences of technique failure and any complication within 90 days were 10% and 38% respectively. The occurrence of complications was not statistically significantly different for outpatients and electively admitted patients. Average costs for catheter insertion were higher in electively hospitalized patients than in outpatients (€2320 ± €960 vs €1346 ± €208, p < 0.000). Conclusions: Compared with an inpatient procedure, outpatient insertion of a PD catheter results in similar outcomes at a lower cost.


  • Implications of Levels of Serum Mineral Metabolism Markers, Albumin and C-Reactive Protein for Treatment Costs of Patients on Maintenance Dialysis

    by Tapani Salonen, Juho Piirto, Tuomo Reina, Heikki Saha, Amos Pasternack

    Background: Secondary hyperparathyroidism, malnutrition and inflammation have been reported to associate with adverse outcomes in dialysis patients. However, little is known about the implications of these conditions for treatment costs. Methods: The cost data of all adult patients who had entered dialysis therapy at Tampere University Hospital between 1991 and 1996 and had remained on dialysis for at least 1 year were collected. Results of measurements of parathyroid hormone (PTH), calcium, phosphorus, albumin and C-reactive protein (CRP) were obtained from the database of the hospital. Results: Patients (n = 109), aged 57.0 ± 14.9 years, included 57% men and 37% diabetics; 62% started on hemodialysis and 38% on peritoneal dialysis. Average daily costs were USD 161 (range 95–360). After controlling for patients’ age, body mass index, gender, dialysis modality and primary renal disease, there was a positive correlation between average CRP and average costs and a negative correlation between albumin and costs. Correlations between mineral metabolism markers and costs were not found, but there was a trend towards lower cost among patients who achieved the Kidney Disease Outcomes Quality Initiative targets of calcium, phosphorus and PTH (USD 145 ± 31) compared with those with nonoptimal levels (USD 165 ± 48; p = 0.095). Costs of patients with at least one in-target PTH measurement were lower than costs of patients with constantly low PTH (USD 148 ± 31 vs. 170 ± 48; p = 0.01). Conclusion: Serum levels of albumin and CRP correlated with dialysis patients’ treatment costs. Achieving the Kidney Disease Outcomes Quality Initiative targets may be associated with lower costs.


  • Alternative strategies to evaluate the cost-effectiveness of peritoneal dialysis and hemodialysis

    by Tapani Salonen, Tuomo Reina, Heikki Oksa, Pekka Rissanen, Amos Pasternack

    Dialysis treatment requires considerable resources and it is important to improve the efficiency of care. Files of all adult end-stage renal disease (ESRD) patients who entered dialysis therapy between 1991 and 1996, were studied and all use of health care resources was recorded. A total of 138 patients started with in-center hemodialysis (HD) and 76 patients with continuous ambulatory peritoneal dialysis (CAPD). Four alternative perspectives were applied to assess effectiveness. An additional analysis of 68 matched CAPD-HD pairs with similar characteristics was completed. Cost-effectiveness ratios (CER; cost per life-year gained) were different in alternative observation strategies. If modality changes and cadaveric transplantations were ignored, annual first three years’ CERs varied between $41220–61465 on CAPD and $44540–85688 on HD. If CAPD-failure was considered as death, CERs were $34466–81197 on CAPD. When follow-up censored at transplantation but dialysis modality changes were ignored, CERs were $59409–95858 on CAPD and $70042–85546 on HD. If observation censored at any change of primarily selected modality, figures were $57731–66710 on CAPD and $74671–91942 on HD. There was a trend of lower costs and better survival on CAPD, the only exception was the strategy in which technical failure of modality was considered as death. Figures of the matched CAPD-HD pairs were very close to the figures of the entire study population. Compared to HD, CERs were slightly lower on CAPD.


  • Cost analysis of renal replacement therapies in Finland

    by Tapani Salonen, Tuomo Reina, Heikki Oksa, Harri Sintonen, Amos Pasternack